Argentina vs Guinea: Average cost of drugs for extensively drug-resistant tuberculosis
Argentina
4,721 constant 2022 US$
in 2024
Guinea
5,356 constant 2022 US$
in 2024
Argentina rank
12th
Guinea rank
9th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Argentina
- Guinea
How they compare
Guinea currently reports 5,356 constant 2022 US$ against 4,721 constant 2022 US$ in Argentina, a difference of 635 constant 2022 US$.
That makes Guinea's figure about 1.1 times Argentina's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Argentina ahead.
Argentina ranks 12th and Guinea ranks 9th of 56 countries.
Across the 2 decades both report, Argentina averaged higher in 1 and Guinea in 1.
Head to head by decade
| Decade | Argentina | Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 9,142 constant 2022 US$ | 8,964 constant 2022 US$ | 178 constant 2022 US$ | Argentina |
| 2020s | 2,508 constant 2022 US$ | 8,060 constant 2022 US$ | 5,552 constant 2022 US$ | Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Argentina or Guinea?
- Guinea, at 5,356 constant 2022 US$ against 4,721 constant 2022 US$ in Argentina as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Argentina and Guinea?
- 635 constant 2022 US$, with Guinea ahead.
- How many years of comparable data are there for Argentina and Guinea?
- 8 years are reported by both, from 2017 to 2024.
- How do Argentina and Guinea rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Argentina ranks 12th and Guinea ranks 9th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.